Jefferies Group LLC Celldex Therapeutics, Inc. Call Options Transaction History

Jefferies Group LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Sep 21, 2023	BUY	$22.7 - $37.57 $919,350 - $1.52 Million	40,500 Added 46.44%	127,700 $3.59 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $919,350 - $1.52 Million	40,500 Added 46.44%	127,700 $3.59 Million
Q2 2022 Sep 21, 2023	BUY	$20.5 - $37.33 $143,500 - $261,310	7,000 Added 8.73%	87,200 $2.35 Million
Q2 2022 Aug 15, 2022	BUY	$20.5 - $37.33 $143,500 - $261,310	7,000 Added 8.73%	87,200 $2.35 Million
Q1 2022 Sep 21, 2023	SELL	$27.64 - $39.32 $478,172 - $680,236	-17,300 Reduced 17.74%	80,200 $2.73 Million
Q1 2022 May 16, 2022	SELL	$27.64 - $39.32 $478,172 - $680,236	-17,300 Reduced 17.74%	80,200 $2.73 Million
Q4 2021 Sep 21, 2023	SELL	$35.68 - $56.27 $1.08 Million - $1.7 Million	-30,200 Reduced 23.65%	97,500 $3.77 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $3.48 Million - $5.49 Million	97,500 New	97,500 $3.77 Million
Q4 2020 Feb 16, 2021	SELL	$14.99 - $22.75 $301,299 - $457,275	-20,100 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$9.65 - $15.19 $193,965 - $305,319	20,100 New	20,100 $298,000

207

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.1B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.